Non-cirrhotic Intrahepatic Portal Hypertension: Associated Gut Diseases and Prognostic Factors
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Non-cirrhotic intrahepatic portal hypertension (NCIPH) is generally regarded to have a benign prognosis. We have studied a cohort followed-up at a tertiary referral center and postulate that gut-derived prothrombotic factors may contribute to the pathogenesis and prognosis of NCIPH.
We retrospectively analyzed prognostic indicators in 34 NCIPH patients. We also searched for associated gut diseases.
Transplant-free survival in NCIPH patients from first presentation with NCIPH at 1, 5, and 10 years was 94% (SE: 4.2%), 84% (6.6%), and 69% (9.8%), respectively. Decompensated liver disease occurred in 53% of patients. Three (9%) patients had ulcerative colitis while five of 31 (16%) tested had celiac disease and on Kaplan–Meier analysis, celiac disease predicted reduced transplant-free survival (p = 0.018). On multivariable Cox regression analysis, independent predictors of reduced transplant-free survival were older age at first presentation with NCIPH, hepatic encephalopathy, and portal vein thrombosis. Prevalence of elevated initial serum IgA anticardiolipin antibody (CLPA) was significantly higher in NCIPH (36% of patients tested), compared to Budd–Chiari syndrome (6%) (p = 0.032, Fisher’s exact test) and celiac disease without concomitant liver disease (0%) (p = 0.007).
We have identified prognostic factors and report progression to liver failure in 53% of NCIPH patients followed-up at our center. Our data supports a role for intestinal disease in the pathogenesis of intrahepatic portal vein occlusion leading to NCIPH.
- Non-cirrhotic Intrahepatic Portal Hypertension: Associated Gut Diseases and Prognostic Factors
Digestive Diseases and Sciences
Volume 56, Issue 1 , pp 227-235
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- Non-cirrhotic portal hypertension
- Celiac disease
- Inflammatory bowel disease
- IgA cardiolipin antibody
- Portal vein thrombosis
- Industry Sectors
- Author Affiliations
- 1. Liver Unit, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK
- 6. Department of GI Sciences, Liver Unit, Christian Medical College, Vellore, Tamil Nadu, 632004, India
- 2. Wellcome Trust Clinical Research Facility, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK
- 3. Department of Pathology, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK
- 4. Clinical Immunology, Division of Immunology and Infection, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK
- 5. Department of Immunology, University of Birmingham, Queen Elizabeth Hospital, Edgbaston, Birmingham, B15 2TH, UK
- 7. Department of Anaesthesiology and Intensive Care Medicine, University Hospital of Patras, 26500, Rion, Greece